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Schizophrenia is a chronic and severely debilitating psychiatric
disorder affecting nearly 1% of the world’s population. In 2002,
the new human gene G72, encoding for the pLG72 protein, and
the gene encoding for D-amino acid oxidase (DAAO) have been
genetically linked to the susceptibility to schizophrenia. A yeast
two-hybrid screening experiment identiﬁed DAAO as a putative
interacting partner of pLG72. DAAO is a FAD-containing ﬂavo-
oxidase that in brain is responsible for the elimination of D-ser-
ine, a co-agonist that binds to the glycine-site of the NMDA
receptor. We recently demonstrated that pLG72 acts as ‘‘inacti-
vator’’ of human DAAO (hDAAO) and that the cellular concen-
tration of D-serine might depend on the expression of the active
form of this ﬂavooxidase. Based on these results, a molecular
model for the onset of schizophrenia has been proposed: a
decrease in pLG72 expression might yield an anomalous high
level of hDAAO activity and therefore a decrease in the local
concentration of D-serine, affecting glutamatergic neurotransmis-
sion mediated by NMDA receptor.
The characterization of the complex is a challenging task, hardly
feasible by high resolution techniques. The main limit is due to
pLG72 since: 1) no structural information is available; 2) it is sol-
uble only in the presence of mild denaturant; 3) no homologous
proteins have been characterized so far. In this perspective, we
have used low resolution strategies based on the coupling of clas-
sical biochemistry approaches (complementary proteolysis, cross-
link) with mass spectrometric techniques, to characterize the
pLG72-hDAAO complex. Results indicated that hDAAO exhib-
its different proteolysis proﬁles when isolated or in complex with
pLG72, thus suggesting a conformational change upon binding
the effector protein. Chemical cross-linking experiments will com-
plement the proteolysis experiments providing with details about
the contact regions between hDAAO e pLG72.
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Hypoxia leads to massive release of neurotransmitter glutamate
during ischemic stroke. Elevation of concentration of intracellular
calcium via NMDA receptor under glutamate excitotoxicity
results in inhibition of mitochondria function including perme-
ability of mitochondrial transition pore, Dw loss and release of
proapoptotic factors. Meanwhile, it is possible to assume direct
signaling pathway linked hypoxia and mitochondria. Our aim
was to study the mitochondria hypoxia sensing mechanism.
We used three models: rat brain homogenates after in vivo com-
mon carotid artery occlusion, homogenates of cortex tissue slices,
and mitochondria isolated from brain using Percoll density cen-
trifugation. Using in vivo model we have shown that after
24 hours of occlusion in rats respiratory control index (RCI) of
mitochondria was reduced from 7.7 ± 0.5 to 4.5 ± 0.3. The
same disruption of phosphorylating system was observed in both
in vitro models of hypoxia (brain slices and isolated brain mito-
chondria). The reduction of RCI was accompanied with
increased of H2O2 generation by isolated mitochondria. The
effects of a modulator (glycine) and an inhibitor (MK-801) of
NMDAR on mitochondrial function were studied. The depletion
of RCI in both in vivo and in vitro models was effectively pre-
vented by glycine. Generation of H2O2 by mitochondria stimu-
lated in anoxia was also signiﬁcantly reduced by MK-801
(10 lM) and glycine (5 mM).
We suggest that one of the possible mechanism of hypoxia sens-
ing by mitochondria could be associated with abundance of the
functional NMDA receptor in the brain mitochondria. NMDAR
agonist glutamate (10–500 lM) added to isolated mitochondria
in the presents of rotenon-e (inhibitor of complex I mitochondrial
respiratory chain) stimulates the generation of H2O2 up to three-
folds. Process was signiﬁcantly reduced by 10 lM MK-801
(inhibitor NMDAR) and 5 mM glycine.
These ﬁndings suggest a novel mechanism by which brain mito-
chondria could directly sense hypoxia during stroke.
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Charcot-Marie-Tooth 1A (CMT1A) is a hereditary neuropathy
associated with overexpression of the peripheral myelin protein
22 (PMP22), causing demyelination. The molecular mechanisms
leading to Schwann cell (SC) dysfunction are not understood and
no treatment is available for CMT1A.
We reported an abnormally high intracellular Ca2+ concentra-
tion (Ca2+) (i) in SC from a rat model of CMT1A (CMT1A
SC), caused by overexpression of the purinergic receptor P2X7.
Correction of the elevated (Ca2+) (i) levels by the use of P2X7
antagonists or through down-regulation of P2X7 expression
restored the normal phenotype in CMT1A SC.
We recently identiﬁed a new P2X7 antagonist, called P18, which
is an isomer of Ap2A. P18 is also an agonist of P2Y11, the only
purinergic receptor increasing the (cAMP) (i) a positive regulator
of SC differentiation.
Organotypic DRG cultures from both wt and CMT1A rats were
treated for 3 weeks with 200 nM P18, or 1 lM A438079 (a com-
mercially available P2X7 antagonist), or 1 mU/ml apyrase. All
treatments signiﬁcantly increase expression levels of the myelin
protein MPZ (by 1.3-, 2.1- and 1.5-fold in CMT1A SC, by 1.4-,
1.1- and 2.3- in wt SC, respectively, as determined by western
blots). Morphometric analysis of DRG, treated with P18 or
A438079, and stained with Sudan black, conﬁrms a signiﬁcant
increase of myelin segment density compared to untreated DRG.
Neuroﬁlament dephosphorylation levels, a measure of the possible
detrimental effect on neurons, are not increased by the treatments.
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